Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Norketotifen in Allergen-Induced Allergic Rhinitis
NCT03887026Phase 2Completed
- Sponsor
- Emergo Therapeutics
- Start
- Apr 2019
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of norketotifen in allergic rhinitis (AR) (3 arms), sponsored by Emergo Therapeutics. Primary endpoint: Change in Total Nasal Symptom Score at 6 hours. Started Apr 2019; status: completed.
02
Drugs
norketotifen
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT03887026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03887026.